Mustang Bio rises after FDA orphan drug status for MB-101
FDA Orphan Drug Status: Mustang Bio's CAR T-cell therapy, MB-101, received orphan drug status from the U.S. FDA for treating astrocytoma and glioblastoma, resulting in a 90% premarket stock increase.
Funding Needs: The company is seeking additional funding or strategic partnerships to advance its MB-109 program targeting recurrent GBM and high-grade astrocytomas.
Trade with 70% Backtested Accuracy
Analyst Views on MBIO
About MBIO
About the author
Ford Unveils 2027 Bronco RTR SUV, Priced Between $51,475 and $80,000
- New Model Launch: Ford has announced the introduction of the 2027 Bronco RTR SUV, the eighth model in the Bronco lineup, designed to blend off-road and street performance, thereby enriching its product offerings.
- Powertrain Specs: The new Bronco RTR will feature a 2.3-liter turbocharged four-cylinder engine delivering 315 horsepower and 350 pound-feet of torque, which, while less powerful than the Bronco Raptor's 418 horsepower, still offers robust performance appealing to off-road enthusiasts.
- Market Positioning: Although Ford has not disclosed specific pricing, the Bronco RTR is expected to be priced between the $51,475 Bronco Heritage Edition and approximately $80,000 for the Bronco Raptor, positioning it as a more accessible performance model.
- Sales Timeline: The Bronco RTR will be available for order starting in October, with sales commencing in January 2027, further enhancing Ford's competitiveness in the SUV market.
Ford Expands Bronco Lineup with New RTR Model Positioned Between $51,475 and $80,000
- New Model Launch: Ford has announced the introduction of the 2027 Bronco RTR SUV, the eighth model in the Bronco lineup, which combines off-road and street performance to attract a broader consumer base.
- Pricing Positioning: While Ford has not disclosed specific pricing, the Bronco RTR is expected to be positioned between the $51,475 Bronco Heritage Edition and the roughly $80,000 Bronco Raptor, making it a more accessible performance model.
- Powertrain Details: The Bronco RTR will feature a 2.3-liter turbocharged four-cylinder engine delivering 315 horsepower and 350 pound-feet of torque, which, although lower than the Raptor's 418 horsepower and 440 pound-feet, still offers robust performance.
- Market Strategy: The launch of this model aligns with Ford's strategy to leverage its well-known brands such as Bronco, Mustang, and F-150, aiming to meet the demand for affordable performance vehicles among off-road enthusiasts.
Cascade Prodrug Inc. Names Industry Experts Manuel (Manny) Litchman and Andres Gutierrez to Its Board of Directors
New Board Appointments: Cascade Prodrug, Inc. has appointed Dr. Manuel Litchman and Dr. Andres Gutierrez to its Board of Directors, enhancing its leadership in oncology-focused biotechnology.
Dr. Litchman's Background: Dr. Litchman brings over 30 years of experience in biopharmaceuticals, having held leadership roles at Mustang Bio and Arvinas, with a strong focus on drug development and oncology.
Dr. Gutierrez's Expertise: Dr. Gutierrez is recognized for his extensive experience in clinical development and oncology, previously serving as Chief Medical Officer at several biotech companies and leading various successful drug trials.
Company Focus: Cascade is developing hypoxia activated therapies, with their lead candidate CPD100Li showing promise against multiple tumor types and entering IND-enabling studies targeting pancreatic cancer and other hypoxic tumors.
Calidi Biotherapeutics Stock Jumps 39% After Hours — What's Going On
Stock Surge: Calidi Biotherapeutics Inc (CLDI) saw a significant after-hours stock surge of 39.47%, increasing its price from $0.24 to $0.34, driven by investor confidence in its innovative cancer treatment approaches.
Market Context: The rise in CLDI's stock coincides with broader movements in the healthcare sector, including notable gains from other biotech companies, indicating heightened investor interest in potential opportunities within the industry.
3 Penny Stocks to Watch Now, 7/8/25
Penny Stocks to Watch: Mustang Bio, Sonnet BioTherapeutics, and SaverOne 2014 Ltd. are highlighted as top penny stocks on July 8, 2025, with significant Dollar Volumes and stock price increases, particularly Mustang Bio which received FDA Orphan Drug Designation for its cancer treatment candidate.
Market Insights: The TipRanks’ Penny Stock Screener tool is utilized to identify these stocks based on various parameters, including market performance metrics like Dollar Volume, which reflects the trading activity of these companies.
Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies
Global Oncology Market Growth: The global oncology market is projected to reach hundreds of billions in revenue due to rising cancer incidence, advancements in therapies like precision medicine and immunotherapy, and increased R&D investment. Breakthrough therapy designations are accelerating drug development and approval processes, enhancing market access for pharmaceutical companies.
Oncolytics Biotech Developments: Oncolytics Biotech has reported promising clinical data for its oncolytic virus immunotherapy, pelareorep, showing significant survival benefits in metastatic pancreatic cancer and breast cancer. The company aims to advance pelareorep into registration-enabling studies, leveraging its fast-track status for regulatory efficiency.
Ford Unveils 2027 Bronco RTR SUV, Priced Between $51,475 and $80,000
- New Model Launch: Ford has announced the introduction of the 2027 Bronco RTR SUV, the eighth model in the Bronco lineup, designed to blend off-road and street performance, thereby enriching its product offerings.
- Powertrain Specs: The new Bronco RTR will feature a 2.3-liter turbocharged four-cylinder engine delivering 315 horsepower and 350 pound-feet of torque, which, while less powerful than the Bronco Raptor's 418 horsepower, still offers robust performance appealing to off-road enthusiasts.
- Market Positioning: Although Ford has not disclosed specific pricing, the Bronco RTR is expected to be priced between the $51,475 Bronco Heritage Edition and approximately $80,000 for the Bronco Raptor, positioning it as a more accessible performance model.
- Sales Timeline: The Bronco RTR will be available for order starting in October, with sales commencing in January 2027, further enhancing Ford's competitiveness in the SUV market.
Ford Expands Bronco Lineup with New RTR Model Positioned Between $51,475 and $80,000
- New Model Launch: Ford has announced the introduction of the 2027 Bronco RTR SUV, the eighth model in the Bronco lineup, which combines off-road and street performance to attract a broader consumer base.
- Pricing Positioning: While Ford has not disclosed specific pricing, the Bronco RTR is expected to be positioned between the $51,475 Bronco Heritage Edition and the roughly $80,000 Bronco Raptor, making it a more accessible performance model.
- Powertrain Details: The Bronco RTR will feature a 2.3-liter turbocharged four-cylinder engine delivering 315 horsepower and 350 pound-feet of torque, which, although lower than the Raptor's 418 horsepower and 440 pound-feet, still offers robust performance.
- Market Strategy: The launch of this model aligns with Ford's strategy to leverage its well-known brands such as Bronco, Mustang, and F-150, aiming to meet the demand for affordable performance vehicles among off-road enthusiasts.
Cascade Prodrug Inc. Names Industry Experts Manuel (Manny) Litchman and Andres Gutierrez to Its Board of Directors
New Board Appointments: Cascade Prodrug, Inc. has appointed Dr. Manuel Litchman and Dr. Andres Gutierrez to its Board of Directors, enhancing its leadership in oncology-focused biotechnology.
Dr. Litchman's Background: Dr. Litchman brings over 30 years of experience in biopharmaceuticals, having held leadership roles at Mustang Bio and Arvinas, with a strong focus on drug development and oncology.
Dr. Gutierrez's Expertise: Dr. Gutierrez is recognized for his extensive experience in clinical development and oncology, previously serving as Chief Medical Officer at several biotech companies and leading various successful drug trials.
Company Focus: Cascade is developing hypoxia activated therapies, with their lead candidate CPD100Li showing promise against multiple tumor types and entering IND-enabling studies targeting pancreatic cancer and other hypoxic tumors.
Calidi Biotherapeutics Stock Jumps 39% After Hours — What's Going On
Stock Surge: Calidi Biotherapeutics Inc (CLDI) saw a significant after-hours stock surge of 39.47%, increasing its price from $0.24 to $0.34, driven by investor confidence in its innovative cancer treatment approaches.
Market Context: The rise in CLDI's stock coincides with broader movements in the healthcare sector, including notable gains from other biotech companies, indicating heightened investor interest in potential opportunities within the industry.
3 Penny Stocks to Watch Now, 7/8/25
Penny Stocks to Watch: Mustang Bio, Sonnet BioTherapeutics, and SaverOne 2014 Ltd. are highlighted as top penny stocks on July 8, 2025, with significant Dollar Volumes and stock price increases, particularly Mustang Bio which received FDA Orphan Drug Designation for its cancer treatment candidate.
Market Insights: The TipRanks’ Penny Stock Screener tool is utilized to identify these stocks based on various parameters, including market performance metrics like Dollar Volume, which reflects the trading activity of these companies.
Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies
Global Oncology Market Growth: The global oncology market is projected to reach hundreds of billions in revenue due to rising cancer incidence, advancements in therapies like precision medicine and immunotherapy, and increased R&D investment. Breakthrough therapy designations are accelerating drug development and approval processes, enhancing market access for pharmaceutical companies.
Oncolytics Biotech Developments: Oncolytics Biotech has reported promising clinical data for its oncolytic virus immunotherapy, pelareorep, showing significant survival benefits in metastatic pancreatic cancer and breast cancer. The company aims to advance pelareorep into registration-enabling studies, leveraging its fast-track status for regulatory efficiency.
